News & Updates
Showing Neurology articles
Showing
Show Multimedia Only

CROWN: 1L lorlatinib improves PFS, reduces CNS progression in ALK-positive NSCLC ± brain metastases
09 Sep 2022
bySarah Cheung
First-line treatment of ALK-positive non-small-cell lung cancer (NSCLC) with lorlatinib improves progression-free survival (PFS) and reduces central nervous system (CNS) progression vs crizotinib, regardless of presence or absence of baseline brain metastases (BM), a post hoc analysis of the phase III CROWN trial has shown.
09 Sep 2022







